Table 1 Clinicopathologic characteristics of the luminal-like MBC cohort.
Characteristics | No | % |
|---|---|---|
BC histological type | ||
 NST | 509 | 84.55 |
 Lobular | 93 | 15.45 |
BC IHC characteristics | ||
 ER +  | 697 | 99.15 |
 PR +  | 464 | 66.67 |
 HER2+ | 0 | 0 |
Metastatic involvement | ||
 Bone | 548 | 78.06 |
 Liver | 290 | 41.31 |
 Lymph nodes | 262 | 37.32 |
 Lung | 221 | 31.48 |
 Soft tissue | 125 | 17.81 |
 CNS | 46 | 6.55 |
Previous treatments | ||
 ET | 452 | 74.10 |
 CT | 257 | 42.13 |
 CDK4/6 inhibitors | 322 | 52.79 |
 mTOR inhibitors | 105 | 17.21 |
 PI3K inhibitors | 38 | 6.23 |
 Immunotherapy | 8 | 1.31 |